Skip to content

Author

M. Vaduganathan

We have 8 of 131 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Finerenone and serum sodium in patients with heart failure and mildly reduced or preserved ejection fraction: an analysis of FINEARTS-HF

Older observational studies in cirrhosis and heart failure (HF) suggest that treatment with spironolactone is frequently associated with hyponatraemia, which is mechanistically plausible given the known actions of aldosterone. However, the effect of the nonsteroidal mineralocorticoid receptor antagonist (nsMRA) f...

R. Ono, K. Docherty, A. Henderson et al. · 0 citations
Open access Oct 2026

Clinical signs of congestion in heart failure across the range of ejection fraction: insights from contemporary randomised trials

Congestion is a hallmark of heart failure (HF) and is associated with a higher risk of hospitalisation and mortality. Bedside signs of congestion are routinely used to assess severity of HF, yet their prevalence and prognostic significance may differ between heart failure with preserved (HFpEF) and reduced ejecti...

A. S. Olesen, S. Sukumar, A. Henderson et al. · 0 citations
Nov 2026

Abstract 6518: Kidney Failure Risk Equation, Clinical Outcomes, and Effect of Finerenone in HFmrEF/HFpEF: Insights from FINEARTS-HF

Background: The Kidney Failure Risk Equation (KFRE) is recommended in international guidelines for estimating the risk of kidney failure in patients with chronic kidney disease (CKD). The prognostic relevance of the KFRE has not been described in patients with heart failure and mildly reduced or preserved ejection f...

R. Ono, K. Docherty, A. Henderson et al. · 0 citations
Open access Oct 2026

Simplified BMI-stratified diagnostic NT-proBNP thresholds in patients with HFpEF

Obesity is associated with lower natriuretic peptide concentrations, potentially reducing the diagnostic accuracy of N-terminal pro–B-type natriuretic peptide (NT-proBNP) for heart failure with preserved ejection fraction (HFpEF). Several body mass index (BMI)–adjusted NT-proBNP thresholds have been proposed, but...

R. Ono, R. Campbell, A. Henderson et al. · 0 citations
Open access Oct 2026

Early magnesium changes may contribute to SGLT2 inhibitor–induced left ventricular mass regression in CKD

Disturbances in the bone and mineral homeostasis are central drivers of cardiovascular disease in chronic kidney disease (CKD), contributing to vascular calcification and left ventricular hypertrophy. In DECODE-CKD, the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin induced significant left ventr...

K. Bartholdy, N. Johansen, D. Modin et al. · 0 citations
Open access Aug 2026

HFpEF-ABA Score and Finerenone in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: Insights From the FINEARTS-HF Trial.

BACKGROUND The HFpEF-ABA score is a simple diagnostic tool developed to estimate the probability of heart failure with preserved ejection fraction (HFpEF) using age, body mass index, and history of atrial fibrillation. OBJECTIVES This study aims to evaluate the HFpEF-ABA score in patients with confirmed heart failure...

R. Ono, K. Docherty, A. Henderson et al. · 0 citations
Open access Aug 2026

Short-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium.

A prediction model is developed to estimate the short-term treatment effects of combination medical therapy on systolic blood pressure (SBP), diastolic BP, estimated glomerular filtration rate (eGFR) and serum potassium and individualized estimates of the expected treatment effect are provided.

Nelson Wang, B. Claggett, M. Pfeffer et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.